Immunohistochemical Expression of Somatostatin Receptor Subtypes in a Panel of Neuroendocrine Neoplasias

Show full item record



Permalink

http://hdl.handle.net/10138/320964

Citation

Remes , S M , Leijon , H L , Vesterinen , T J , Arola , J T & Haglund , C H 2019 , ' Immunohistochemical Expression of Somatostatin Receptor Subtypes in a Panel of Neuroendocrine Neoplasias ' , Journal of Histochemistry and Cytochemistry , vol. 67 , no. 10 , pp. 735-743 . https://doi.org/10.1369/0022155419856900

Title: Immunohistochemical Expression of Somatostatin Receptor Subtypes in a Panel of Neuroendocrine Neoplasias
Author: Remes, Satu M.; Leijon, Helena L.; Vesterinen, Tiina J.; Arola, Johanna T.; Haglund, Caj H.
Contributor: University of Helsinki, Department of Pathology
University of Helsinki, HUSLAB
University of Helsinki, HUSLAB
University of Helsinki, Department of Pathology
University of Helsinki, HUS Abdominal Center
Date: 2019-10
Language: eng
Number of pages: 9
Belongs to series: Journal of Histochemistry and Cytochemistry
ISSN: 0022-1554
URI: http://hdl.handle.net/10138/320964
Abstract: Neuroendocrine neoplasias (NENs) are known to express somatostatin receptors (SSTRs) 1-5, which are G-protein-coupled cell membrane receptors. Somatostatin receptor imaging and therapy utilizes the SSTR expression. Synthetic somatostatin analogs with radioligands are used to detect primary tumors, metastases, and recurrent disease. Receptor analogs are also used for treating NENs. Furthermore, commercially available SSTR antibodies can be used for the immunohistochemical (IHC) detection of SSTRs. We investigated different SSTR antibody clones applying diverse IHC protocol settings to identify reliable clones and feasible protocols for NENs. A tissue microarray including NENs from 12 different primary sites were stained. Only UMB clones were able to localize SSTR on the cell membranes of NENs. SSTR2 (UMB1) emerged as the most common subtype followed by SSTR5 (UMB4) and SSTR1 (UMB7). SSTR3 (UMB5) expression was mainly cytoplasmic. Yet, SSTR4 expression was weak and located primarily in the cytoplasm. Thus, appropriate IHC protocols, including proper positive and negative controls, represent requirements for high-quality NEN diagnostics and for planning personalized therapy.
Subject: immunohistochemistry
neuroendocrine tumor
somatostatin receptor
MONOCLONAL-ANTIBODIES
TISSUES
REASSESSMENT
VALIDATION
SSTR2A
TUMORS
1182 Biochemistry, cell and molecular biology
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
0022155419856900.pdf 593.1Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record